Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

Lymphatic Mapping Of Oropharyngeal Cancer

Sponsor: University College, London

NCT ID: NCT04498221

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Imaging procedure (procedure), Surgical procedure (procedure)
How long the study runs
Study runs about 54 months (dates as stated)
About the drug or intervention
Imaging procedure — procedure: During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan · Surgical procedure — procedure: Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic.
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years and over
Who
All
Number of participants
150
Started
2022-07-07
Last checked
2024-09

Plain English Summary

What is this study?

  • • Testing a new treatment for oropharyngeal cancer
  • • NA - 150 participants
  • • A multi-centre validation study to evaluate whether a new imaging and surgical protocol would work as well as the current gold standard in identifying sentinel nodes in patients with oropharyngeal cancer

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with oropharyngeal cancer

Where?

  • • London - St George's University Hospitals NHS Foundation Trust
  • • London - University College Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

A multi-centre validation study to evaluate whether a new imaging and surgical protocol would work as well as the current gold standard in identifying sentinel nodes in patients with oropharyngeal cancer.

More detail

Cancer at the back of the mouth and throat is usually discovered after it has spread to lymph glands in the neck. Treatment therefore involves dealing with both the original tumour (in the mouth/throat) and the spread cancer in the lymph glands. This type of cancer sometimes spreads to both sides of the neck, not just the side on which the original tumour was located. The decision as to whether to treat the other side of the neck as well depends on various factors including the aggressiveness of the tumour, whether the patient smokes and whether or not the Human Papilloma Virus (HPV) is present in the tumour. This is inevitably inexact, and assessing the likelihood of the cancer spreading to the other side of the neck always involves an element of estimation. Some patients end up being treated unnecessarily on both sides (often with severe and lasting effects on swallowing, meaning they have to use a feeding tube), while others receive treatment on one side only but the cancer comes back on the other side. This study will provide more accurate information on which to base the decision as to whether to treat the other side of the neck. The study will use a procedure known as sentinel node biopsy (SNB) to establish (with a high degree of accuracy) whether or not the cancer has spread to the other side of the neck. The study will be in two stages. The first stage is the imaging stage. A very low does of a radioactive tracer substance will be injected into the tumour. The radioactive tracers used in this study are either Human albumin colloidal particles or Lymphoseek. Once injected, they move quickly into the lymph nodes and can then be detected using a handheld gamma camera. The first nodes that the radiotracer moves into are the "sentinel" nodes. Patients already undergo an examination under anaesthetic (EUA); the patients participating in the study will have the radiotracer injected additionally and the sentinel nodes detected during this EUA. The use of the handheld camera is relatively new; so, all of the patients in the study will also have a CT scan the next day to double check whether the handheld camera identified the sentinel nodes correctly. The second stage of the study, the surgery stage, will involve a new group of patients having the imaging procedure. Those who do have sentinel nodes in the other side of the neck will have them removed during the EUA. Those nodes will then be examined thoroughly for signs of cancer. A separate limb of stage one of the study will involve some patients whose main tumours are easily accessible also having their tumour injected with the radiotracer a second time under local anaesthetic in an outpatient clinic. In the study this will take place several days after the initial injection with the radiotracer. If this procedure is found to be acceptable to patients, it would mean that patients could have the radiotracer injected before the EUA, thereby allowing time for the sentinel nodes to be identified by CT scan so that they can be removed during the EUA. This will provide a way to ensure that, even if the handheld camera cannot be used, the sentinel nodes can still be removed while the patient is under anaesthetic for the EUA. If the study is successful, the patient will be able to have much more accurate information about whether their cancer has, or might, spread to the other side of the neck, without having to undergo an additional general anaesthetic.

Oropharyngeal Cancer

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

Biomarkers mentioned

P16 negativeP16 positive

What the study is looking for

  • ✓Adults aged 18 or over
  • ✓New diagnosis of OPC - all anatomical subsites and HPV status accepted
  • ✓Unilateral that has spread nodes equating to AJCC TNM8 clinical staging N1-N2b for P16 negative and N1 for P16 positive...

Who cannot take part

  • ✗Suspicious bilateral nodes on imaging
  • ✗Previous radiotherapy or surgery to the neck
  • ✗Second primary oropharyngeal tumours
  • ✗Distant metastasis (e.g. lung, bone)
  • ✗Pregnancy and lactation
See the full criteria
Inclusion Criteria: * Adults aged 18 or over * New diagnosis of OPC - all anatomical subsites and HPV status accepted * Unilateral metastatic nodes equating to AJCC TNM8 clinical staging N1-N2b for P16 negative and N1 for P16 positive patients. Exclusion Criteria: * Suspicious bilateral nodes on imaging * Previous radiotherapy or surgery to the neck * Second primary oropharyngeal tumours * Distant metastasis (e.g. lung, bone) * Pregnancy and lactation * Inability to give informed consent * Allergy to lymphatic tracers

Where Is This Study? (2 UK sites)

St George's University Hospitals NHS Foundation Trust

London SW17 0QT, United Kingdom

Recruiting
Hospital R&D contact (matched)

Mr Subhir Bedi

researchgovernance@sgul.ac.uk020 8725 4986

University College Hospital

London, United Kingdom

Recruiting
Site contact (verified)
Clare Schillingncita.looc@ucl.ac.uk

How to Get in Touch

Trial Manager

Sponsor contact

CONTACT

02076799274 ncita.looc@ucl.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2024-09